explore -WSS

explore

author：focus 2025-09-30 22:06:15 - browse：56

People in business and medical wardrobe in a table discussion — coverage from STAT — Adobe

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Food makers to regulators: Ultra

WSS

7 of the most gruesome medical devices in history

Diverse clinical trials: Why aren’t we there yet?

Russian special forces kill a gunman who broke into a private house near Moscow

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Marvel Studios reveals new trailer for 'The Marvels': Watch here

FDA panel endorses Alnylam’s heart drug — after picking it apart

leisure time

explore

focus

Virginia high school admissions case could be legal follow

FDA official pushes for dedicated emerging pathogens team

Tori Bowie and the unacceptable rates of Black maternal death

HIPAA doesn't protect reproductive records from prosecutors

Malaria cases in Florida and Texas: Here’s what you need to know

FDA proposes changes to key medical devices approval pathway

BioMarin wins approval for gene therapy to treat hemophilia A

AbbVie dramatically boosts its spending on lobbying

Medicare proposal to cover medical devices draws a mixed reaction

Regeneron agrees to White House price limits on anti

explore

Organ transplantation is at a crossroads. Major reform is needed

FDA proposes changes to key medical devices approval pathway

Russian special forces kill a gunman who broke into a private house near Moscow

Review: 'Barbie' will hit you like a shot in the heart

Diverse clinical trials: Why aren’t we there yet?

PEPFAR is under serious threat — and so is global health

leisure time

hotspot

focus

hotspot